EUVIMEDEUVIMED entdecken
Crossref

Integrating CyTOF with scRNA-seq reveals that Cyclovirobuxine D inhibits HCC progression through hepatic immune microenvironment remodeling

Fuqiang Ma, Lele Zhang, Yitao Fan, Ziyi Xu, Yuhua He, Jiachun Sun, Juan Lu, Xinyu Gu

Phytomedicine · 2026-01 · 150 · 157751

DOI: 10.1016/j.phymed.2025.157751 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2026-01. Verfasst von Fuqiang Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrated Traditional and Western Medicine, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science a…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Tumor Microenvironment, Liver Neoplasms, Antineoplastic Agents, Phytogenic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hepatocellular carcinoma (HCC) represents the predominant type of primary malignant liver cancer, characterized by high morbidity and mortality rates. The steroidal alkaloid cyclovirobuxine D (CVB-D), which is extracted from Buxus microphylla, has garnered increasing attention for its potential in anti-tumor research. Despite this, the immunoregulatory effects of CVB-D in HCC remain insufficiently explored. PURPOSE: This study investigated the role and underlying mechanisms of CVB-D in inhibiting HCC progression, aiming to identify potential therapeutic targets and provide new scientific evidence for HCC treatment. STUDY DESIGN: CVB-D was administrated to orthotopic HCC mouse models. The effects of CVB-D on the tumor immune microenvironment were systematically assessed via integrated cytometry by time of flight (CyTOF) and single-cell RNA sequencing (scRNA-seq). METHODS: An orthotopic HCC model was generated in C57BL/6 mice via Hepa1-6 cell implantation, followed by intraperitoneal administration of different doses of CVB-D. Following a 14-day treatment period, fresh tumor tissues were collected for CyTOF and scRNA-seq analyses. Multiplexed immunofluorescence staining was performed on liver tissue sections to validate the in suit localization of key biomarkers. Serum cytokine levels were evaluated utilizing the Quantibody® Mouse Inflammation Array Kit. RESULTS: This research demonstrated that administration of CVB-D in orthotopic HCC mouse models notably inhibited tumor progression. Comprehensive analyses combining CyTOF and scRNA-seq demonstrated that CVB-D remodeled the hepatic immune microenvironment by enhancing CD8+T cell functionality, modulating macrophage polarization, and reducing the abundance of malignant epithelial cells. CONCLUSION: These findings highlight the therapeutic promise of CVB-D as a novel candidate for HCC treatment, offering new insights into the development of innovative anti-cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularTumor MicroenvironmentLiver NeoplasmsAntineoplastic Agents, PhytogenicAnimalsMice, Inbred C57BLMiceCell Line, TumorMaleRNA-SeqHumansDisease ProgressionSingle-Cell AnalysisSingle-Cell Gene Expression Analysis

Stichwörter der Autor:innen

CyTOFCyclovirobuxine DHCCImmunoregulatoryTherapeutic strategyscRNA-seq

Substanzen

Antineoplastic Agents, Phytogenic

Autor:innen und Institutionen

  • Department of Integrated Traditional and Western Medicine, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang 471003, Henan, China.
  • Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang 471003, Henan, China.
  • Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang 471003, Henan, China. Electronic address: Su…
  • State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Di…
  • Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang 471003, Henan, China. Electronic address: hk…

Förderung

  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Ma, F., Zhang, L., Fan, Y., Xu, Z., He, Y., Sun, J., Lu, J., & Gu, X. (2026). Integrating CyTOF with scRNA-seq reveals that Cyclovirobuxine D inhibits HCC progression through hepatic immune microenvironment remodeling. Phytomedicine, 150, 157751. https://doi.org/10.1016/j.phymed.2025.157751

Vancouver

Ma F, Zhang L, Fan Y, Xu Z, He Y, Sun J, et al. Integrating CyTOF with scRNA-seq reveals that Cyclovirobuxine D inhibits HCC progression through hepatic immune microenvironment remodeling. Phytomedicine. 2026;150:157751. doi:10.1016/j.phymed.2025.157751

BibTeX
@article{Ma2026,
  author = {Ma, Fuqiang and Zhang, Lele and Fan, Yitao and Xu, Ziyi and He, Yuhua and Sun, Jiachun and Lu, Juan and Gu, Xinyu},
  title = {Integrating CyTOF with scRNA-seq reveals that Cyclovirobuxine D inhibits HCC progression through hepatic immune microenvironment remodeling},
  journal = {Phytomedicine},
  year = {2026},
  volume = {150},
  pages = {157751},
  doi = {10.1016/j.phymed.2025.157751}
}
Kostenlos starten →